True targeting-derived prostate biopsy: HistoScanning™ remained inadequate despite advanced technical efforts
Standard
True targeting-derived prostate biopsy: HistoScanning™ remained inadequate despite advanced technical efforts. / Schiffmann, Jonas; Mehring, Gisa; Tennstedt, Pierre; Manka, Lukas; Boehm, Katharina; Leyh-Bannurah, Sami-Ramzi; Karakiewicz, Pierre I; Hammerer, Peter; Graefen, Markus; Salomon, Georg.
In: WORLD J UROL, Vol. 34, No. 4, 04.2016, p. 495-500.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - True targeting-derived prostate biopsy: HistoScanning™ remained inadequate despite advanced technical efforts
AU - Schiffmann, Jonas
AU - Mehring, Gisa
AU - Tennstedt, Pierre
AU - Manka, Lukas
AU - Boehm, Katharina
AU - Leyh-Bannurah, Sami-Ramzi
AU - Karakiewicz, Pierre I
AU - Hammerer, Peter
AU - Graefen, Markus
AU - Salomon, Georg
PY - 2016/4
Y1 - 2016/4
N2 - PURPOSE: To verify the reliability of HistoScanning™-based, true targeting (TT)-derived prostate biopsy.METHODS: We relied on 40 patients suspicious for prostate cancer who underwent standard and TT-derived prostate biopsy. Sensitivity, specificity, positive predictive value, negative predictive value and the area under the curve (AUC) were assessed for the prediction of biopsy results per octant by HistoScanning™, using different HistoScanning™ signal volume cutoffs (>0, >0.2 and >0.5 ml).RESULTS: Overall, 319 octants were analyzed. Of those, 64 (20.1 %) harbored prostate cancer. According to different HistoScanning™ signal volume cutoffs (>0, >0.2 and >0.5 ml), the AUCs for predicting biopsy results were: 0.51, 0.51 and 0.53, respectively. Similarly, the sensitivity, specificity, positive predictive and negative predictive values were: 20.7, 78.2, 17.4 and 81.6 %; 20.7, 82.0, 20.3 and 82.3 %; and 12.1, 94.6, 33.3 and 82.9 %, respectively.CONCLUSIONS: Prediction of biopsy results based on HistoScanning™ signals and TT-derived biopsies was unreliable. Moreover, the AUC of TT-derived biopsies was low and did not improve when additional signal volume cutoffs were applied (>0.2 and >0.5 ml). We cannot recommend a variation of well-established biopsy standards or reduction in biopsy cores based on HistoScanning™ signals.
AB - PURPOSE: To verify the reliability of HistoScanning™-based, true targeting (TT)-derived prostate biopsy.METHODS: We relied on 40 patients suspicious for prostate cancer who underwent standard and TT-derived prostate biopsy. Sensitivity, specificity, positive predictive value, negative predictive value and the area under the curve (AUC) were assessed for the prediction of biopsy results per octant by HistoScanning™, using different HistoScanning™ signal volume cutoffs (>0, >0.2 and >0.5 ml).RESULTS: Overall, 319 octants were analyzed. Of those, 64 (20.1 %) harbored prostate cancer. According to different HistoScanning™ signal volume cutoffs (>0, >0.2 and >0.5 ml), the AUCs for predicting biopsy results were: 0.51, 0.51 and 0.53, respectively. Similarly, the sensitivity, specificity, positive predictive and negative predictive values were: 20.7, 78.2, 17.4 and 81.6 %; 20.7, 82.0, 20.3 and 82.3 %; and 12.1, 94.6, 33.3 and 82.9 %, respectively.CONCLUSIONS: Prediction of biopsy results based on HistoScanning™ signals and TT-derived biopsies was unreliable. Moreover, the AUC of TT-derived biopsies was low and did not improve when additional signal volume cutoffs were applied (>0.2 and >0.5 ml). We cannot recommend a variation of well-established biopsy standards or reduction in biopsy cores based on HistoScanning™ signals.
U2 - 10.1007/s00345-015-1637-x
DO - 10.1007/s00345-015-1637-x
M3 - SCORING: Journal article
C2 - 26215749
VL - 34
SP - 495
EP - 500
JO - WORLD J UROL
JF - WORLD J UROL
SN - 0724-4983
IS - 4
ER -
